Q3 2017 EPS Estimates for ContraFect Corporation Raised by Analyst (CFRX)
ContraFect Corporation (NASDAQ:CFRX) – Zacks Investment Research lifted their Q3 2017 EPS estimates for ContraFect Corporation in a research report issued on Monday. Zacks Investment Research analyst D. Bautz now anticipates that the biotechnology company will earn ($0.11) per share for the quarter, up from their previous forecast of ($0.18). Zacks Investment Research also issued estimates for ContraFect Corporation’s Q4 2017 earnings at ($0.10) EPS, FY2017 earnings at ($0.43) EPS, FY2018 earnings at ($0.41) EPS and FY2019 earnings at ($0.48) EPS.
ContraFect Corporation (NASDAQ:CFRX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.11.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/q3-2017-eps-estimates-for-contrafect-corporation-raised-by-analyst-cfrx/1493967.html.
Separately, Maxim Group restated a “hold” rating on shares of ContraFect Corporation in a research note on Wednesday, April 19th.
ContraFect Corporation (CFRX) opened at 1.20 on Wednesday. The firm has a 50-day moving average of $1.34 and a 200-day moving average of $1.60. The stock’s market capitalization is $49.99 million. ContraFect Corporation has a 1-year low of $1.10 and a 1-year high of $3.28.
A hedge fund recently bought a new stake in ContraFect Corporation stock. Westfield Capital Management Co. LP purchased a new position in ContraFect Corporation (NASDAQ:CFRX) during the first quarter, according to its most recent filing with the SEC. The institutional investor purchased 149,600 shares of the biotechnology company’s stock, valued at approximately $269,000. Westfield Capital Management Co. LP owned about 0.36% of ContraFect Corporation at the end of the most recent quarter. Hedge funds and other institutional investors own 25.22% of the company’s stock.
In related news, Director Sol J. Barer purchased 40,000 shares of ContraFect Corporation stock in a transaction dated Tuesday, July 25th. The stock was purchased at an average cost of $1.24 per share, for a total transaction of $49,600.00. Following the completion of the purchase, the director now directly owns 815,933 shares of the company’s stock, valued at approximately $1,011,756.92. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders bought 50,800 shares of company stock valued at $62,992 over the last quarter. Company insiders own 9.30% of the company’s stock.
Receive News & Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.